Zymeworks (ZYME) Reiterated at Market Outperform by Citizens on FDA Approval for Zani

August 26, 2026 4:21 AM

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found